title: Prognostic factors for patients with Hodgkin disease in first relapse.
abstract: BACKGROUND
  This study aims to identify factors that predict outcome after salvage therapy for patients with Hodgkin disease (HD) in first relapse.
  
  
  METHODS
  Between 1969 and 1985, 627 patients with Pathologic Stage IA-IIIB HD were treated at the Joint Center for Radiation Therapy. With a median follow-up time for survivors of 135 months, 138 patients (22%) have experienced relapse. One hundred twenty-seven of these were retreated with curative intent and form the basis of this report.
  
  
  RESULTS
  The complete response (CR) rate after retreatment was 79%. The 10-year actuarial freedom from second relapse (FSR) was 53%, and the 10-year survival rate from the time of first relapse was 57%. For patients experiencing relapse after initial radiation therapy (RT) alone (n = 110), the 10-year FSR and overall survival rates were 58% and 62%, respectively. Histologic type was the single most important prognostic factor for second CR rate, FSR, and survival. Patients with nodular sclerosis or lymphocyte predominant (NS/LP) histologic type had a 91% second CR rate, 67% 10-year FSR rate, and 75% 10-year survival rate, compared with 66%, 44%, and 43%, respectively, for patients with mixed cellularity or lymphocyte depleted (MC/LD) histologic type. For patients who experienced relapse after initial combined modality therapy (CMT; n = 17), the 10-year FSR and overall survival rates were 13% and 24%, respectively.
  
  
  CONCLUSIONS
  This study demonstrates that patients who experience relapse after RT alone can be effectively salvaged with combination chemotherapy. The implications of these results for clinical decision making are discussed.
authors.affiliation: Joint Center for Radiation Therapy, Boston, MA 02115.
authors.forename: E A
authors.initials: EA
authors.lastname: Healey
authors.forename: N J
authors.initials: NJ
authors.lastname: Tarbell
authors.forename: L A
authors.initials: LA
authors.lastname: Kalish
authors.forename: B
authors.initials: B
authors.lastname: Silver
authors.forename: D S
authors.initials: DS
authors.lastname: Rosenthal
authors.forename: K
authors.initials: K
authors.lastname: Marcus
authors.forename: L N
authors.initials: LN
authors.lastname: Shulman
authors.forename: C N
authors.initials: CN
authors.lastname: Coleman
authors.forename: G
authors.initials: G
authors.lastname: Canellos
authors.forename: H
authors.initials: H
authors.lastname: Weinstein
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D012008:Recurrence; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome